Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are studying MK-5684, a medicine designed to block the body from making steroid hormones, to see if it can treat breast cancer, ovarian cancer, and endometrial cancer. The study compares MK-5684 to standard treatments for these cancers. The goal is to find out if people receiving MK-5684 live longer without their cancer growing or spreading than those receiving standard treatment. Participants with breast, ovarian, or endometrial cancer will be assigned to different treatment groups. Those with breast cancer receive MK-5684 with corticosteroids or endocrine therapy chosen by their doctor. Participants with ovarian cancer will be observed without treatment. Those with endometrial cancer receive one of several hormone therapies chosen by their doctor. Treatments continue until certain conditions to stop are met. During the study, participants will take oral medicines or receive injections based on their group. Researchers will monitor cancer progression, overall survival, response rates, and side effects for up to about two years. Safety and treatment effects will be carefully tracked. The study starts with screening and continues until the primary outcomes are measured, lasting up to approximately two years.
Actively Recruiting
Researchers are evaluating the drug opevesostat in comparison to alternative hormonal therapies abiraterone acetate or enzalutamide for adults with metastatic castration-resistant prostate cancer mCRPC who have previously been treated with next-generation hormonal agents and taxane-based chemotherapy. This phase 3, randomized, open-label study aims to determine if opevesostat improves overall survival in participants both with and without androgen receptor ligand binding domain mutations. Participants are randomly assigned to receive either opevesostat 5 mg orally twice daily combined with dexamethasone 1.5 mg once daily and fludrocortisone acetate 0.1 mg once daily, or alternative therapies consisting of abiraterone 1000 mg once daily with prednisone 5 mg twice daily, or enzalutamide 160 mg once daily. Hydrocortisone is provided as rescue medication as needed. Treatment continues until disease progression. During the study, participants undergo regular assessments including monitoring overall survival, radiographic progression-free survival, time to subsequent therapies, response duration, pain progression, prostate-specific antigen levels, and safety evaluations for adverse events. The study may last up to approximately 54 months for key outcome measures, with ongoing monitoring to assess treatment effects and participant safety throughout the trial.
Actively Recruiting
This trial evaluates the safety and effectiveness of Volrustomig in women with high-risk locally advanced cervical cancer FIGO 2018 stage IIIA to IVA who have not shown disease progression after platinum-based concurrent chemoradiation therapy CCRT. It is a global, randomized, double-blind, placebo-controlled Phase III study designed to assess outcomes in this specific patient population. Participants are randomly assigned in equal numbers to receive either Volrustomig or a placebo via intravenous infusion. The study compares these two groups to explore the potential benefits and risks of Volrustomig as a treatment following CCRT in women with high-risk locally advanced cervical cancer. Women taking part in the study will undergo multiple assessments over up to approximately seven years. Researchers monitor progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, subsequent therapies, and safety. Additional evaluations include tumor progression, pharmacokinetics, immunogenicity, adverse events, and patient-reported symptoms and quality of life. Participants provide tumor samples and undergo regular health evaluations during this period.